Nanchang Third Hospital

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Osteoporosis1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 32 trials
• Phase 1/21 trial

Status

• Active, not recruiting2 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Shanghai Henlius Biotech2 trials
• Biotheus Inc.1 trial
• Daiichi Sankyo1 trial

Running trials

• Recruiting

  A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

  NCT06210776· Daiichi Sankyo· Source

  Contact: Daiichi Sankyo China

• Active, not recruiting

  A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

  NCT05918133· Phase 1/2· Biotheus Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

  NCT05346224· Phase 3· Shanghai Henlius Biotech· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

  NCT05352516· Phase 3· Shanghai Henlius Biotech· Source